The selection of embryos with higher implantation potential remains at the centre of ongoing research in the field of reproductive medicine and assisted conception.
Preimplantation genetic testing for aneuploidies (PGT-A) aims to deselect embryos with the wrong chromosomal complement and improve live birth rates. A recent publication by Somigliana et al. in the June 2019 issue of Fertility and Sterility showed that PGT-A carried out in human blastocysts can be cost-effective in women aged 35 and older that have at least 3 blastocysts available after IVF and undergo elective single embryo transfer.
Here at the Reproductive Health Group in Cheshire the laboratory team has expertise in blastocyst biopsy and the clinical team recommends the use of PGT-A in IVF cycles in selected groups of patients, including those with repeated implantation failures, recurrent early miscarriages and older than 35 years with 3 or more good quality blastocysts.
Learn more about PGT-A here.